⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin to Present at 38th Annual ROTH Conference
globenewswire.com
MBRX
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners
accessnewswire.com
MBRX
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
globenewswire.com
MBRX
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
globenewswire.com
MBRX
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
globenewswire.com
MBRX
Moleculin Launches CEO Corner Platform to Share Strategic Insights
globenewswire.com
MBRX